scholarly journals Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study

2020 ◽  
Vol Volume 12 ◽  
pp. 6575-6583
Author(s):  
Xuan Wu ◽  
Jingxun Wu ◽  
Gangling Tong ◽  
Boran Cheng ◽  
Minhua Chen ◽  
...  
Keyword(s):  
Retrospective Study ◽  
High Risk ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
Gastrointestinal Tumor ◽  
Antiemetic Regimen

Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9111-9111 ◽  
Author(s):  
S. M. Grunberg ◽  
M. Dugan ◽  
H. B. Muss ◽  
M. Wood ◽  
S. Burdette-Radoux ◽  
...  
Keyword(s):  
Adverse Events ◽  
Rescue Medication ◽  
Complete Response ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
Antiemetic Regimen ◽  
Delayed Nausea ◽  
Pre Treatment ◽  
Significant Nausea

9111 Background: Serotonin antagonists, NK-1 antagonists (NKA) and corticosteroids (C) have all shown efficacy against chemotherapy-induced nausea and vomiting. However these agents are commonly used in cumbersome and inconvenient multiple day regimens that can also raise questions of compliance. Palonosetron is a serotonin antagonist with a 40 hour half-life, requiring only one dose for several days of exposure. Single high doses of NKA and C can also be used to simulate drug exposures achieved with a multiple day regimen. We have therefore evaluated a 1-day 3-drug antiemetic regimen for 5 day efficacy against moderately emetogenic chemotherapy. Methods: Patients with solid tumors receiving their first cycle of cyclophosphamide and/or doxorubicin were eligible to receive a single pre-treatment dose of palonosetron 0.25 mg IV/dexamethasone 20 mg PO/aprepitant 285 mg PO. Nausea and vomiting were evaluated over the following 5 days with a patient diary including vomiting episodes, use of rescue medication, and daily nausea visual analogue scale (VAS). Patients were urged to begin rescue medication for nausea, vomiting, or related discomfort. Endpoints included Complete Response (CR) (no emesis or rescue), No Emesis (NE), and No Significant Nausea (NSN) (VAS<25) during the acute period (A) (Day 1), the delayed period (D) (Days 2–5), and the overall period (O) (Days 1–5). Adverse events were recorded and tabulated for at least 14 days. Results: 32 of 40 planned patients have been entered on study. 31 women and 1 man with breast cancer receiving adjuvant chemotherapy with median age 52 years (range 34–74) have been treated and all are evaluable. CR for A/D/O was 78%/59%/50%. However NE for A/D/O was 100%/97%/97%, and NSN for A/D/O was 75%/62%/56%. Only 8 patients had more than one day of Significant Nausea. The most common treatment-related adverse events were fatigue and mild headache. Conclusions: A 1-day 3-drug antiemetic regimen is feasible and effective, and should be tested against a multiple day standard antiemetic regimen. [Table: see text]

The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy

1998 ◽  
Vol 6 (4) ◽  
pp. 389-395 ◽  
Author(s):  
J. J. Rusthoven ◽  
David Osoba ◽  
Charles A. Butts ◽  
Louise Yelle ◽  
Helen Findlay ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
The Impact

scholarly journals Effectiveness of antiemetics in control of antineoplastic chemotherapy-induced emesis at home

2014 ◽  
Vol 27 (5) ◽  
pp. 412-418 ◽  
Author(s):  
Marielly Cunha Castro ◽  
Suely Amorim de Araújo ◽  
Thaís Rezende Mendes ◽  
Glauciane Silva Vilarinho ◽  
Maria Angélica Oliveira Mendonça
Keyword(s):  
Breast Cancer ◽  
Emetogenic Chemotherapy ◽  
Nausea And Vomiting ◽  
Moderately Emetogenic Chemotherapy ◽  
Medical Prescription ◽  
Acute Emesis ◽  
Antineoplastic Chemotherapy ◽  
At Home

Objective Evaluating if antiemetics are effective in the prevention or treatment at home, of chemotherapy-induced emesis. Methods In total, were included 42 women with breast cancer in moderately emetogenic chemotherapy, using dexamethasone/ondansetron before each cycle. The frequency of nausea and vomiting was obtained by applying the instrument in the pre-chemotherapy period, and 24h, 48h, 72h and 96h after chemotherapy. The use of antiemetics was considered in accordance with adherence to medical prescription. Results All patients (n = 42, 100%) reported emesis at some point. Only five cases (11.9%) were anticipatory. In the first 24 hours (acute emesis), 38 (90.5%)ayed), emesis was reported by all despite the regular use (n = 20, 47.6%) or not (n = 22, 52.4%) of antiemetics (ondansetron, dexamethasone and metoclopramide/or dimenhydrinate). Conclusion Antiemetics were not effective in the prevention or treatment at home, of chemotherapy-induced emesis.

Sign in / Sign up

Export Citation Format

Share Document